IMM · ImmuPharma plc

0.037

GBP

-0.0002 (-0.404%)

22/10/2026 12:00:00 AM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

GBP23.18M

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 22/10/2026 12:00:00 AM

Price Chart

Description

ImmuPharma PLC engages in the research, development, and commercialization of pharmaceutical products. It is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm's portfolio consists of four novel peptide therapy areas: autoimmunity, metabolism, cancer and anti-infectives. Its drug Lupuzor, is a potential treatment for the autoimmune chronic inflammatory disease lupus. The company was founded by Richard Warr and Dimitri F. Dimitriou in 1999 and is headquartered in London, the United Kingdom.

All-Companies
Big Candle
Consensus Expensive
HALO All

Key Fundamentals

EPS 3 yr Growth

-70.60%

EBITDA Margin

N/A

Operating Cashflow

-£2m

Free Cash Flow Return

NaN%

ROIC

NaN%

Interest Coverage

-287.50

Quick Ratio

1.50

Performance

52 weeks range

Low 0.03 - 0.14

Trade Value (12mth)

US$54,699.00

1 week

-2.37%

1 month

-6.66%

YTD

-40.08%

1 year

-67.97%

All time high

1.94

Additional Data

Shares Outstanding (Fully Diluted)

559m

HALO Sector

Healthcare

Next Company Report Date

25-May-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

GBP

Short Sell (% of issue)

0.00

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
15 September 26RNS
15 September 26RNS
15 September 26RNS
10 September 26RNS
10 August 26RNS

Key Stakeholders

Name	Title
Lanstead Capital Investors LP	Private Company
Clearstream Banking SA	Subsidiary
Consorsbank	Private Company
Elisabeth Zimmer	Individual
Stichting DeGiro	Foundation/Endowment